

type of report	Current report
number	4/2012
company	PHARMENA

Share capital increase of Cortria Corporation

The Management Board of PHARMENA S.A. informs that on 19th January 2012, the Issuer increased share capital of subsidiary company Cortria Corporation by 800,000 USD (through issue of new shares).

The objective of the issue is to conclude works over documentation and research plans in order to continue clinical trials (on people). Cortria Corporation carries out studies on innovative anti-atherosclerosis medicinal product (1-MNA) in USA and Canada.

Cortria Corporation is a private pharmaceutical company with registered headquarters in USA, which conducts clinical trials focusing on developing safe and well-tolerated medicinal products for the treatment of cardiovascular diseases, particularly atherosclerosis.

The information is made public due to the Issuer's participation in potential revenue resulting from commercialisation of patents and patent applications for the use of 1-MNA active substance, which is investigated by Cortria and which PHARMENA S.A. possesses rights to.

The Issuer's purchase of additional shares in the Cortria company constitutes realisation of one of the goals of an issue of PHARMENA S.A. series B shares.

Legal basis: Alternative Trading System Rules – Exhibit 3 “Current and Periodical Information in the Alternative Trading System on the NewConnect Market”, Article 3 (1).

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board